This page shows the latest Elenbecestat news and features for those working in and with pharma, biotech and healthcare.
The announcement of aducanumab’s demise as well as the failure of AC Immune and Roche’s crenezumab and other amyloid-targeting agents including Biogen/Eisai’s elenbecestat and Amgen/Novartis’
The departure comes after a difficult few months in which Biogen has pulled the plug on two of its amyloid-targeting Alzheimer’s disease programmes – aducanumab and elenbecestat – after disappointing efficacy
Follows discontinuation of Eisai-partnered Alzheimer's drug. Just a few days after calling time on its Eisai-partnered Alzheimer’s drug elenbecestat, Biogen has another pipeline casualty – this time its
Latest blow in string of failures for BACE inhibitor category. In a potential final blow to the BACE inhibitor treatment category, Biogen and Eisai have discontinued trials of elenbecestat after the ... The failure of elenbecestat comes on the heels
The loss of CNP520 leaves just one major BACE inhibitor standing – Eisai and Biogen’s elenbecestat.
The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... Meanwhile, Eisai says in an update published today that it is
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....